Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jul;63(7):836–842. doi: 10.1136/ard.2003.008516

Burden and cost of illness in patients with juvenile idiopathic arthritis

K Minden 1, M Niewerth 1, J Listing 1, T Biedermann 1, M Schontube 1, A Zink 1
PMCID: PMC1755057  PMID: 15194580

Abstract

Objective: To estimate the cost of illness in an incidence based cohort of patients with juvenile idiopathic arthritis.

Methods: Direct costs (healthcare and non-healthcare costs) and indirect costs (productivity loss due to sick leave and work disability) were measured in 215 JIA patients, assessed on an average of 17 years after disease onset. Assessment included a clinical evaluation, a structured interview, and two self completion questionnaires. Annual direct costs were estimated based on the reported use of healthcare services and resources, using average unit prices. Indirect costs were estimated from the number of work days missed—that is, using the human capital approach.

Results: The mean total cost of late JIA was estimated to be €3500 per patient and year, of which the direct cost contributed more than half. Patients with still active disease (55%) incurred the major share (90%) of the cost. They had a mean total cost of €5700 per patient year, with those under rheumatological care incurring a cost of €9300. Having a certain JIA subgroup, functional disability, or receipt of specialised care independently contributed to the total cost in active JIA. Highest mean total costs were found in active seropositive polyarthritis (€17 000) and extended oligoarthritis (€11 000), while the lowest were found in active enthesitis related arthritis (€1500) and persistent oligoarthritis (€2700).

Conclusions: Estimated 12 month costs in late JIA are considerable, differing among the various JIA subgroups. Treatment strategies in JIA should be analysed for their cost effectiveness in the long term.

Full Text

The Full Text of this article is available as a PDF (119.6 KB).

Figure 1.

Figure 1

Open in a new tab

 Direct costs incurred by patients not in remission v those having attained remission.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaire S. H., DeNardo B. S., Szer I. S., Meenan R. F., Schaller J. G. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992 Jun;19(6):952–955. [PubMed] [Google Scholar]
  2. Barrett E. M., Scott D. G., Wiles N. J., Symmons D. P. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 2000 Dec;39(12):1403–1409. doi: 10.1093/rheumatology/39.12.1403. [DOI] [PubMed] [Google Scholar]
  3. Boonen A., van der Heijde D., Landewé R., Spoorenberg A., Schouten H., Rutten-van Mölken M., Guillemin F., Dougados M., Mielants H., de Vlam K. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002 May;61(5):429–437. doi: 10.1136/ard.61.5.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brouwer W. B. F., van Exel N. J. A., Koopmanschap M. A., Rutten F. F. H. Productivity costs before and after absence from work: as important as common? Health Policy. 2002 Aug;61(2):173–187. doi: 10.1016/s0168-8510(01)00233-0. [DOI] [PubMed] [Google Scholar]
  5. Cooper N. J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000 Jan;39(1):28–33. doi: 10.1093/rheumatology/39.1.28. [DOI] [PubMed] [Google Scholar]
  6. Cooper N. J., Mugford M., Scott D. G., Barrett E. M., Symmons D. P. Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK. J Rheumatol. 2000 Sep;27(9):2115–2122. [PubMed] [Google Scholar]
  7. Cooper N. J., Mugford M., Symmons D. P. M., Barrett E. M., Scott D. G. I. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology (Oxford) 2002 Jul;41(7):767–774. doi: 10.1093/rheumatology/41.7.767. [DOI] [PubMed] [Google Scholar]
  8. Cummins Carole, Connock M., Fry-Smith A., Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess. 2002;6(17):1–43. doi: 10.3310/hta6170. [DOI] [PubMed] [Google Scholar]
  9. Fautrel Bruno, Guillemin Francis. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol. 2002 Mar;14(2):121–126. doi: 10.1097/00002281-200203000-00008. [DOI] [PubMed] [Google Scholar]
  10. Flatø Berit, Lien Gunhild, Smerdel Anna, Vinje Odd, Dale Knut, Johnston Virginia, Sørskaar Dag, Moum Torbjørn, Ploski Rafal, Førre Øystein. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003 Feb;30(2):386–393. [PubMed] [Google Scholar]
  11. Jonsson D., Husberg M. Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care. 2000 Autumn;16(4):1193–1200. doi: 10.1017/s0266462300103228. [DOI] [PubMed] [Google Scholar]
  12. Kobelt Gisela, Jönsson Linus, Lindgren Peter, Young Adam, Eberhardt Kerstin. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002 Sep;46(9):2310–2319. doi: 10.1002/art.10471. [DOI] [PubMed] [Google Scholar]
  13. Lapsley H. M., March L. M., Tribe K. L., Cross M. J., Courtenay B. G., Brooks P. M., Arthritis Cost and Outcome Project Group Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis. 2002 Sep;61(9):818–821. doi: 10.1136/ard.61.9.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lautenschläger J., Mau W., Kohlmann T., Raspe H. H., Struve F., Brückle W., Zeidler H. Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). Z Rheumatol. 1997 May-Jun;56(3):144–155. doi: 10.1007/s003930050030. [DOI] [PubMed] [Google Scholar]
  15. Leardini G., Salaffi F., Montanelli R., Gerzeli S., Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol. 2002 Jul-Aug;20(4):505–515. [PubMed] [Google Scholar]
  16. Merkesdal S., Ruof J., Mittendorf T., Mau W., Zeidler H. Gesundheitsökonomische Forschung im Bereich der chronischen Polyarthritis. Z Rheumatol. 2002 Feb;61(1):21–29. doi: 10.1007/s003930200003. [DOI] [PubMed] [Google Scholar]
  17. Minden Kirsten, Niewerth Martina, Listing Joachim, Biedermann Thomas, Bollow Matthias, Schöntube Monika, Zink Angela. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002 Sep;46(9):2392–2401. doi: 10.1002/art.10444. [DOI] [PubMed] [Google Scholar]
  18. Packham J. C., Hall M. A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (Oxford) 2002 Dec;41(12):1436–1439. doi: 10.1093/rheumatology/41.12.1436. [DOI] [PubMed] [Google Scholar]
  19. Packham J. C., Hall M. A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002 Dec;41(12):1428–1435. doi: 10.1093/rheumatology/41.12.1428. [DOI] [PubMed] [Google Scholar]
  20. Peterson L. S., Mason T., Nelson A. M., O'Fallon W. M., Gabriel S. E. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. 1997 Dec;40(12):2235–2240. doi: 10.1002/art.1780401219. [DOI] [PubMed] [Google Scholar]
  21. Petty R. E., Southwood T. R., Baum J., Bhettay E., Glass D. N., Manners P., Maldonado-Cocco J., Suarez-Almazor M., Orozco-Alcala J., Prieur A. M. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998 Oct;25(10):1991–1994. [PubMed] [Google Scholar]
  22. Pinals R. S., Masi A. T., Larsen R. A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981 Oct;24(10):1308–1315. doi: 10.1002/art.1780241012. [DOI] [PubMed] [Google Scholar]
  23. Pincus T., Callahan L. F., Brooks R. H., Fuchs H. A., Olsen N. J., Kaye J. J. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med. 1989 Feb 15;110(4):259–266. doi: 10.7326/0003-4819-110-4-259. [DOI] [PubMed] [Google Scholar]
  24. Pugner K. M., Scott D. I., Holmes J. W., Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000 Apr;29(5):305–320. doi: 10.1016/s0049-0172(00)80017-7. [DOI] [PubMed] [Google Scholar]
  25. Reginster J. Y. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002 Apr;41(Suppl 1):3–6. [PubMed] [Google Scholar]
  26. Thomas Elaine, Symmons Deborah P. M., Brewster David H., Black Roger J., Macfarlane Gary J. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003 May;30(5):958–965. [PubMed] [Google Scholar]
  27. Ward Michael M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 2002 Jan;46(1):223–231. doi: 10.1002/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  28. Wong J. B., Ramey D. R., Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum. 2001 Dec;44(12):2746–2749. doi: 10.1002/1529-0131(200112)44:12<2746::aid-art461>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  29. Zak M., Pedersen F. K. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000 Feb;39(2):198–204. doi: 10.1093/rheumatology/39.2.198. [DOI] [PubMed] [Google Scholar]
  30. Zink A., Mau W., Schneider M. Epidemiologische und sozialmedizinische Aspekte entzündlich-rheumatischer Systemerkrankungen. Internist (Berl) 2001 Feb;42(2):211-6, 219-22. doi: 10.1007/s001080050745. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES